S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27
S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27
S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27
S&P 500   4,549.78
DOW   35,603.08
QQQ   377.27
NASDAQ:RUBY

Rubius Therapeutics Stock Forecast, Price & News

$16.28
+0.30 (+1.88 %)
(As of 10/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.96
$16.29
50-Day Range
$15.96
$24.62
52-Week Range
$4.20
$38.71
Volume152,069 shs
Average Volume873,454 shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.54
30 days | 90 days | 365 days | Advanced Chart
Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Rubius Therapeutics logo

About Rubius Therapeutics

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RUBY
Employees
204
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.74 per share

Profitability

Net Income
$-167.73 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.46 billion
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.13 out of 5 stars

Medical Sector

439th out of 1,359 stocks

Biological Products, Except Diagnostic Industry

68th out of 196 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

Is Rubius Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Rubius Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View analyst ratings for Rubius Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Rubius Therapeutics?

Wall Street analysts have given Rubius Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rubius Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its earnings results on Monday, August, 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.08.
View Rubius Therapeutics' earnings history
.

How has Rubius Therapeutics' stock price been impacted by COVID-19?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RUBY stock has increased by 148.5% and is now trading at $16.28.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RUBY?

3 equities research analysts have issued 1-year price targets for Rubius Therapeutics' stock. Their forecasts range from $20.00 to $40.00. On average, they anticipate Rubius Therapeutics' share price to reach $28.33 in the next twelve months. This suggests a possible upside of 74.0% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Pablo J. Cagnoni, President, Chief Executive Officer & Director
  • Dannielle Appelhans, Chief Operating Officer
  • Jose Carmona, Treasurer, Chief Financial & Accounting Officer
  • Spencer Fisk, Senior Vice President-Technical Operations
  • Christina Coughlin, Chief Medical Officer

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics CEO Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among Rubius Therapeutics' employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (5.23%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Rubius Therapeutics
.

Which institutional investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co.. Company insiders that have sold Rubius Therapeutics company stock in the last year include David R Epstein, and Maiken Keson-Brookes.
View insider buying and selling activity for Rubius Therapeutics
or view top insider-selling stocks.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $16.28.

How much money does Rubius Therapeutics make?

Rubius Therapeutics has a market capitalization of $1.46 billion. The company earns $-167.73 million in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

Rubius Therapeutics employs 204 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

Where are Rubius Therapeutics' headquarters?

Rubius Therapeutics is headquartered at 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 679-9600 or via email at [email protected].


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.